Form 4: Maze Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Jason Coloma V, Chief Executive Officer and a Director of Maze Therapeutics, Inc., sold 34,501 shares of common stock on October 1, 2026.
Summary
- Open-market sale: disposed of 2,593 Common Stock at $27.02 ($70,073) on October 1, 2026; holds 15,558 after (Indirect).
- Open-market sale: disposed of 31,908 Common Stock at $27.02 ($862,186) on October 1, 2026; holds 191,447 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $932,260 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jason Coloma V — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Open-market sale | Common Stock | 2,593 | $27 | $70.1K | 15,558 |
| 2026-10-01 | Open-market sale | Common Stock | 31,908 | $27 | $862.2K | 191,447 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Open-market sale (2,593 shares) |
| 2026-10-01 | Open-market sale (31,908 shares) |
Keywords
insider transaction, Form 4, MAZE, Maze Therapeutics, Inc., bearish, Jason Coloma V
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.